HOTH News and Press, Hoth Therapeutics Inc. From 04/23/20

NEW YORK , April 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET .  Dr. Poznansky will be pro...

NEW YORK , April 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET .  Dr. Poznansky will be providin...

NEW YORK , April 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. ...

The FDA has signed off on Fast Track status for Yantai, China-based RemeGen 's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE). More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...

NEW YORK , April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky , Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes ...

April 9, 2020 Palm Beach, FL – April 9, 2020 – Recent industry reports on the projected growth of the global dermatologicals markets predict a continued surge in revenues. A report from Allied Market Research said that the global dermatologicals market is expected to...

NEW YORK , April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatolog...

NEW YORK , April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunot...

NEW YORK , March 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full licensing rights of VNLG-152 ...

Astrotech (NASDAQ: ASTC ) +59%  as breathTest -1000 confirmed to detect lung disease metabolites at parts per billion. More news on: Astrotech Corporation, MFA Financial, Inc., Hoth Therapeutics, Inc., Stocks on the move, , Read more ...